Feb 25, 2021
CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4
Feb 24, 2021
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 10, 2021
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 28, 2021
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 06, 2020
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting
Nov 10, 2020
CTI BioPharma Reports Third Quarter 2020 Financial Results
Nov 04, 2020
CTI BioPharma Announces Oral Presentation at the 62nd American Society of Hematology Meeting
Nov 02, 2020
CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020
Oct 13, 2020
CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Aug 06, 2020
CTI BioPharma Reports Second Quarter 2020 Financial Results
Jun 01, 2020
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
May 28, 2020
CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4
Apr 08, 2020
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15
Mar 12, 2020
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 06, 2020
CTI BioPharma Announces Closing of Rights Offering
Feb 14, 2020
CTI BioPharma Announces Commencement of Rights Offering
Feb 03, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
Feb 03, 2020
CTI BioPharma Announces Proposed Rights Offering
Nov 04, 2019
CTI BioPharma Reports Third Quarter 2019 Financial Results
Oct 01, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia